View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 31, 2022

Accutar doses first patient in Phase I prostate cancer treatment trial

The trial will analyse the safety, tolerability, pharmacokinetics and initial anti-tumour activity of AC0176 for mCRPC.

Accutar Biotechnology has dosed the first subject in the Phase I clinical trial of its investigational therapy, AC0176, to potentially treat metastatic castration-resistant prostate cancer (mCRPC) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An orally bioavailable, chimeric degrader molecule, AC0176 is created to act on the androgen receptor (AR) with increased selectivity and potency.

The activation of AR, a hormone-regulated transcription factor, plays a crucial role in the development and progression of prostate cancer. 

The open-label, multicentre trial will analyse the safety, tolerability, pharmacokinetics and initial anti-tumour activity of AC0176 in individuals with mCRPC. 

It will enrol subjects who have advanced after receiving a minimum of two systemic therapies.

Establishing the recommended dose of AC176 that can be administered to trial subjects is one of the keys goals of the trial. 

AC0176 was found to offer robust AR protein degradation with a wide coverage of AR mutants in preclinical studies. 

It also was found to have favourable pharmacological properties and anti-tumour activity in animal models.

In December last year, the company obtained clearance for its investigational new drug application (IND) from the US Food and Drug Administration (FDA) to commence the trial of AC0176 for mCRPC. 

Accutar Biotechnology CEO Jie Fan said: “The initiation of this study marks the second programme from our AI-enabled drug discovery platform and our chimeric degrader portfolio to enter the clinic. 

“AC0176 was designed to potently degrade both AR wildtype and prevalent AR mutants which confer drug resistance to current AR-targeted therapies, including but not limited to L702H, T878A, H875Y, W742C. 

“We are excited about the differentiated therapeutic profile of AC0176 and its broad potential to treat prostate cancer patients.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena